TY - JOUR
T1 - Epidemiology and surveillance for hepatocellular carcinoma
T2 - New trends
AU - Singal, Amit G.
AU - Lampertico, Pietro
AU - Nahon, Pierre
N1 - Funding Information:
Dr. Singal’s research is supported by National Cancer Institute (NCI) R01 CA212008 and CA222900 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding agencies had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation of the manuscript. Dr Nahon’s research is sponsored by the ANRS (France REcherche Nord & sud SIDA-HIV Hépatites: FRENSH) and Banque Publique d’Investissement. The funding sponsors had no role in the design and conduct of the study, the collection, management, analysis, interpretation of data, or the preparation, review, or approval of the manuscript.
Funding Information:
Amit G. Singal has has served on advisory boards for Gilead, Abbvie, Bayer, Eisai, Bristol Meyers Squibb, Wako Diagnostics, and Exact Sciences. He serves as a consultant to Bayer, Eisai, Exelixis, Roche, Exact Sciences, Glycotest, and TARGET. He has received research funding from Gilead and Abbvie. Pierre Nahon has received honoraria from and/or consults for Abbvie, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Gilead, Ipsen and MSD. He received research grants from Abbvie and Bristol-Myers Squibb. Pietro Lampertico has served on speakers' bureau/advisory boards for BMS, Roche, Gilead Sciences, GSK, MSD, Abbvie and Janssen, Eiger, Myr pharma. Please refer to the accompanying ICMJE disclosure forms for further details.
Funding Information:
Dr. Singal's research is supported by National Cancer Institute (NCI) R01 CA212008 and CA222900. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding agencies had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation of the manuscript. Dr Nahon's research is sponsored by the ANRS (France REcherche Nord & sud SIDA-HIV Hépatites: FRENSH) and Banque Publique d'Investissement. The funding sponsors had no role in the design and conduct of the study, the collection, management, analysis, interpretation of data, or the preparation, review, or approval of the manuscript.
Publisher Copyright:
© 2019 European Association for the Study of the Liver
PY - 2020/2
Y1 - 2020/2
N2 - The burden of hepatocellular carcinoma (HCC) is highest in East Asia and Africa, although its incidence and mortality are rapidly rising in the United States and Europe. With the implementation of hepatitis B vaccination and hepatitis C treatment programmes worldwide, the epidemiology of HCC is shifting away from a disease predominated by viral hepatitis – an increasing proportion of cases are now attributable to non-alcoholic steatohepatitis. Surveillance using ultrasound, with or without alpha-fetoprotein, every 6 months has been associated with improved early detection and improved overall survival; however, limitations in implementation lead to a high proportion of HCC being detected at late stages in clinical practice. Herein, we review the current state of HCC surveillance and highlight areas for future research, including improved risk stratification of at-risk patients, surveillance tools with higher sensitivity and specificity for early HCC, and interventions to increase surveillance utilisation.
AB - The burden of hepatocellular carcinoma (HCC) is highest in East Asia and Africa, although its incidence and mortality are rapidly rising in the United States and Europe. With the implementation of hepatitis B vaccination and hepatitis C treatment programmes worldwide, the epidemiology of HCC is shifting away from a disease predominated by viral hepatitis – an increasing proportion of cases are now attributable to non-alcoholic steatohepatitis. Surveillance using ultrasound, with or without alpha-fetoprotein, every 6 months has been associated with improved early detection and improved overall survival; however, limitations in implementation lead to a high proportion of HCC being detected at late stages in clinical practice. Herein, we review the current state of HCC surveillance and highlight areas for future research, including improved risk stratification of at-risk patients, surveillance tools with higher sensitivity and specificity for early HCC, and interventions to increase surveillance utilisation.
UR - http://www.scopus.com/inward/record.url?scp=85076566224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076566224&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2019.08.025
DO - 10.1016/j.jhep.2019.08.025
M3 - Review article
C2 - 31954490
AN - SCOPUS:85076566224
SN - 0168-8278
VL - 72
SP - 250
EP - 261
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 2
ER -